JNCE

Jounce Therapeutics Inc.

Price

return (12m)

p/e

1.10

p/bv

0.53

DIVIDEND YIELD

0.00%

JNCE price

Jounce Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

today you would have:

*The amount considers the reinvestment of dividends.

Return on Investment JNCE

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

today you would have:

Fundamentals JNCE

Valuation

P/E

1.10

Sector -3.16

Industry -3.16

P/BV

0.53

Sector 1.80

Industry 1.80

P/Revenue (PSR)

Sector 2.05

Industry 2.05

EV/EBITDA

Sector -210.13

Industry -210.13

EV/EBIT

Sector -36.38

Industry -36.38

P/EBITDA

1.11

Sector -19.73

Industry -19.73

P/EBIT

1.11

Sector -67.09

Industry -67.09

P/Total Assets

0.46

Sector 1.06

Industry 1.06

P/Net Current Assets

Sector -9.56

Industry -9.56

P/Working Capital

Sector -93.54

Industry -93.54

EPS

1.71

Sector -1.78

Industry -1.78

BVPS

3.54

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

100.00%

Sector 41.27%

Industry 41.27%

EBITDA Margin

61.39%

Sector -21,198.78%

Industry -21,198.78%

EBIT Margin

-18.02%

Sector -35.28%

Industry -35.28%

Net Profit Margins

100.00%

Sector -35.71%

Industry -35.71%

Asset Turnover

0.39

Sector 0.03

Industry 0.03

Profitability

ROE

48.21%

Sector -61.33%

Industry -61.33%

ROA

41.53%

Sector -54.29%

Industry -54.29%

ROIC

Sector -1,801.33%

Industry -1,801.33%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

Sector 2.91

Industry 2.91

Net Debt / EBITDA

Sector -20.88

Industry -20.88

Net Debt / EBIT

Sector -3.40

Industry -3.40

Net Debt / Equity

Sector -34,305.41

Industry -34,305.41

Gross Debt / Equity

Sector -0.81

Industry -0.81

Equity/Assets

0.86

Sector 0.46

Industry 0.46

Liabilities/Assets

0.86

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

24.97%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals JNCE

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Jounce Therapeutics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$0.00

Fair Value

$11.67

Upside

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
JNCE Jounce Therapeutics Inc.	$0.00	-	0.00%	1.10	0.53	48.21%	100.00%
PFE Pfizer Inc.	$29.34	29.45%	5.59%	43.90	1.99	4.43%	6.34%
ABBV AbbVie Inc.	$289.47	37.80%	2.31%	53.66	0.00	-%	14.76%
NVO Novo Nordisk A/S	$40.24	-9.17%	4.66%	9.73	5.17	60.28%	35.32%
MRK Merck & Co. Inc.	$146.62	78.84%	2.26%	151.28	8.26	5.07%	3.64%
AZN AstraZeneca PLC	$185.93	12.89%	1.71%	25.01	5.71	24.18%	18.97%
GILD Gilead Sciences Inc.	$167.61	40.09%	1.94%	45.45	16.08	26.68%	14.89%
BMY Bristol-Myers Squibb Company	$62.45	40.35%	5.06%	13.78	5.44	44.06%	18.47%
ZTS Zoetis Inc.	$79.97	-32.35%	2.60%	12.71	10.64	64.91%	27.69%
AMGN Amgen Inc.	$461.90	49.19%	2.13%	28.86	21.58	91.47%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$898.12	39.39%	0.41%	21.68	2.96	14.04%	27.86%
HALO Halozyme Therapeutics Inc.	$104.69	53.28%	0.00%	37.10	106.90	173.67%	24.86%
MCK McKesson Corporation	$1,056.55	25.75%	0.34%	25.96	-30.85	-168.45%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$546.20	30.98%	0.00%	34.82	6.62	20.80%	30.61%
CAH Cardinal Health Inc.	$266.52	36.72%	0.81%	34.74	-21.86	-63.98%	0.67%
ARGX argenx SE	$903.39	8.53%	0.00%	13.26	-	-%	25.42%
HRMY Harmony Biosciences Holdings Inc.	$33.09	5.55%	0.00%	12.39	2.25	20.46%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

today you would have:

*This calculation reflects price variation only.

JNCE - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Jounce Therapeutics

Jounce Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

14 years

Founded: 2012

2017

Time since IPO - 9 years

128

Employees

Jounce Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $97.18 million, with shareholders equity totaling $183.11 million.

The company employs approximately 128 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Jounce Therapeutics Inc. reported $82.00 million in revenue, generating net income of $88.28 million.

Key financial metrics include a P/E ratio of 1.10, a price-to-book (P/B) ratio of 0.53, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker JNCE.

Market cap

$97.18 million

Net worth

$183.11 million

$183,112,000.00

Assets

$212.55 million

$212,550,000.00

Total Shares Outstanding

51.69 million

51,694,000

Average Daily Trading Volume

$3.01 million

$3,010,032.58

Sector

Health Care

Industry

Biotechnology

JNCE

JNCE revenue and profits

Financial Results JNCE

DRAG THE FRAME TO SEE MORE DATA

JNCE cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$1,056.55 23,65% (12M)

P/E

25.96

0.34%

ROE

-168.45%

P/BV

-30.85

CAH - Cardinal Health

$266.52 35,89% (12M)

P/E

34.74

0.81%

ROE

-63.98%

P/BV

-21.86

MRK - Merck & Co.

$146.62 75,94% (12M)

P/E

151.28

2.26%

ROE

5.07%

P/BV

8.26

ABBV - AbbVie

$289.47 36,37% (12M)

P/E

53.66

2.31%

ROE

P/BV

0.00

PFE - Pfizer

$29.34 28,20% (12M)

P/E

43.90

5.59%

ROE

4.43%

P/BV

1.99

AZN - AstraZeneca

$185.93 11,81% (12M)

P/E

25.01

1.71%

ROE

24.18%

P/BV

5.71

BMY - Bristol-Myers Squibb

$62.45 39,87% (12M)

P/E

13.78

5.06%

ROE

44.06%

P/BV

5.44

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$1,056.55 23,65% (12 M)

P/L

25.96

0.34%

ROE

-168.45%

P/VP

-30.85

CAH - Cardinal Health

$266.52 35,89% (12 M)

P/L

34.74

0.81%

ROE

-63.98%

P/VP

-21.86

MRK - Merck & Co.

$146.62 75,94% (12 M)

P/L

151.28

2.26%

ROE

5.07%

P/VP

8.26

ABBV - AbbVie

$289.47 36,37% (12 M)

P/L

53.66

2.31%

ROE

P/VP

0.00

PFE - Pfizer

$29.34 28,20% (12 M)

P/L

43.90

5.59%

ROE

4.43%

P/VP

1.99

AZN - AstraZeneca

$185.93 11,81% (12 M)

P/L

25.01

1.71%

ROE

24.18%

P/VP

5.71

BMY - Bristol-Myers Squibb

$62.45 39,87% (12 M)

P/L

13.78

5.06%

ROE

44.06%

P/VP

5.44

Frequently Asked Questions

What is the price of Jounce Therapeutics (JNCE) today?

The current price of Jounce Therapeutics (JNCE) is $0.00. The stock began the year trading around $0.00 and is currently priced at $0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Jounce Therapeutics (JNCE) pay dividends?

Jounce Therapeutics (JNCE) did not pay dividends over the past year.

Is Jounce Therapeutics (JNCE) a good investment?

Jounce Therapeutics (JNCE) is currently trading at $0.00 with a P/E ratio of 1.10. This represents a 27% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Jounce Therapeutics (JNCE) stock?

You can buy Jounce Therapeutics (JNCE) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol JNCE and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Jounce Therapeutics (JNCE) yield today?

Over the past month, Jounce Therapeutics (JNCE) has returned 0.00% — 0.00% over the past year, and 0.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Jounce Therapeutics (JNCE) today at the current price of $0.00 your total investment would be $0.00.

Based on historical performance, the investment would have grown to approximately:

$0.00 after 1 year
$0.00 after 5 years
$0.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

JNCE

Jounce Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment JNCE

Target price created!

Delete target price?

Your Target Price strategy deserves unlimited alerts

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING JNCE WITH OTHER STOCKS

ABOUT Jounce Therapeutics

Jounce Therapeutics Inc.

United States

14 years

2017

128

PROFIT X PRICE JNCE

Financial Results JNCE

JNCE cash flow

Asset, Revenue and Profit Growth - JNCE

JNCE balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

BMY - Bristol-Myers Squibb

Frequently Asked Questions